Membranous Nephropathy
Conditions
Interventions
Experimental Group:The experimental group receives the corresponding syndrome-specific Chinese medicine granules used in this trial, in addition to the baseline therapy, stratified therapy, and follow
Control Group:The Control Group receives baseline therapy + stratified therapy + placebo Chinese medicine granules.
Sponsors
Hangzhou Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria for idiopathic membranous nephropathy; (2) Age between 18 and 75 years (inclusive), regardless of gender; (3) Classified as low, moderate, or high risk according to the 2021 KDIGO guideline risk stratification; (4) Glomerular filtration rate (GFR) >30 ml/min; (5) Present with Qi deficiency and blood stasis pattern based on Traditional Chinese Medicine syndrome differentiation; (6) Voluntarily agree to participate in the study, comply with scheduled follow-ups, and provide signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Age under 18 or over 75 years; (2) Diagnosed with secondary membranous nephropathy (SMN), such as patients with MN pathological manifestations caused by viral infections, malignancies, etc.; (3) Patients with a familial genetic predisposition to MN; (4) Use of glucocorticoids or immunosuppressants within the past month; (5) Classified as very high risk according to the 2021 KDIGO guidelines, or presenting with drug-resistant fluid overload, hyperkalemia, metabolic acidosis, severe anemia, etc., requiring consideration of renal replacement therapy; (6) Complicated with severe infections; (7) Pregnant or lactating women, individuals with psychiatric disorders, allergic constitution, or multiple drug allergies; (8) Allergy to Chinese herbal medicine granules; (9) Participation in other clinical drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proteinuria; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum albumin;Traditional Chinese Medicine Syndrome Scoring;Anti-PLA2R levels;24-hour urinary protein quantification;Urine albumin/creatinine;Glomerular filtration rate;Modified Kidney Disease Quality of Life Short Form (KDQOL-SF); | — |
Countries
China
Contacts
Public ContactZhu Caifeng
Hangzhou Hospital of Traditional Chinese Medicine
Outcome results
None listed